Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

606 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A Three-dimensional Ex Vivo Viability Assay Reveals a Strong Correlation Between Response to Targeted Inhibitors and Mutation Status in Melanoma Lymph Node Metastases.
Flørenes VA, Flem-Karlsen K, McFadden E, Bergheim IR, Nygaard V, Nygård V, Farstad IN, Øy GF, Emilsen E, Giller-Fleten K, Ree AH, Flatmark K, Gullestad HP, Hermann R, Ryder T, Wernhoff P, Mælandsmo GM. Flørenes VA, et al. Among authors: mcfadden e. Transl Oncol. 2019 Jul;12(7):951-958. doi: 10.1016/j.tranon.2019.04.001. Epub 2019 May 13. Transl Oncol. 2019. PMID: 31096111 Free PMC article.
Soluble AXL is ubiquitously present in malignant serous effusions.
Flem Karlsen K, McFadden E, Flørenes VA, Davidson B. Flem Karlsen K, et al. Among authors: mcfadden e. Gynecol Oncol. 2019 Feb;152(2):408-415. doi: 10.1016/j.ygyno.2018.11.012. Epub 2018 Nov 15. Gynecol Oncol. 2019. PMID: 30448261
Soluble AXL as a marker of disease progression and survival in melanoma.
Flem-Karlsen K, Nyakas M, Farstad IN, McFadden E, Wernhoff P, Jacobsen KD, Flørenes VA, Mælandsmo GM. Flem-Karlsen K, et al. Among authors: mcfadden e. PLoS One. 2020 Jan 9;15(1):e0227187. doi: 10.1371/journal.pone.0227187. eCollection 2020. PLoS One. 2020. PMID: 31917795 Free PMC article.
Ticagrelor or Clopidogrel Monotherapy vs Dual Antiplatelet Therapy After Percutaneous Coronary Intervention: A Systematic Review and Patient-Level Meta-Analysis.
Valgimigli M, Gragnano F, Branca M, Franzone A, da Costa BR, Baber U, Kimura T, Jang Y, Hahn JY, Zhao Q, Windecker S, Gibson CM, Watanabe H, Kim BK, Song YB, Zhu Y, Vranckx P, Mehta S, Ando K, Hong SJ, Gwon HC, Serruys PW, Dangas GD, McFadden EP, Angiolillo DJ, Heg D, Calabrò P, Jüni P, Mehran R; Single Versus Dual Antiplatelet Therapy (Sidney-3) Collaboration. Valgimigli M, et al. Among authors: mcfadden ep. JAMA Cardiol. 2024 May 1;9(5):437-448. doi: 10.1001/jamacardio.2024.0133. JAMA Cardiol. 2024. PMID: 38506796
Abbreviated or Standard Dual Antiplatelet Therapy by Sex in Patients at High Bleeding Risk: A Prespecified Secondary Analysis of a Randomized Clinical Trial.
Landi A, Alasnag M, Heg D, Frigoli E, Malik FTN, Gomez-Blazquez I, Pourbaix S, Chieffo A, Spaulding C, Sainz F, Routledge H, Andò G, Testa L, Sciahbasi A, Contractor H, Jepson N, Mieres J, Imran SS, Noor H, Smits PC, Valgimigli M; MASTER DAPT Investigators. Landi A, et al. JAMA Cardiol. 2024 Jan 1;9(1):35-44. doi: 10.1001/jamacardio.2023.4316. JAMA Cardiol. 2024. PMID: 37991745 Clinical Trial.
606 results